VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs

This article was originally published here

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM

The post VenatoRx initiates enrollment in phase 3 trial of cefepime/VNRX-5133 in cUTIs appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply